{
    "nctId": "NCT02061423",
    "briefTitle": "HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy",
    "officialTitle": "Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Participation Compliance",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \u2265 18 years.\n* HER-2 expressing stage I - III breast cancer with residual disease in the breast or axillary nodes post-neoadjuvant chemotherapy.\n* Women of childbearing age with a negative pregnancy serum test documented prior to enrollment.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.\n* Women of childbearing potential must agree to use a medically acceptable form of birth control during their participation in the study.\n* Have voluntarily signed a written Informed Consent in accordance with institutional policies after its contents have been fully explained to them.\n\nExclusion Criteria:\n\n* Pregnant or lactating.\n* Positive for HIV or hepatitis C at baseline by self report.\n* Potential participants with coagulopathies, including thrombocytopenia with platelet count \\<75,000, INR \\> 1.5 and partial thromboplastin time \\> 50 sec.\n* Potential participants with MUGA \\< 50% EF.\n* Pre-existing medical illnesses or medications which might interfere with the study as determined by Principal Investigator (PI).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}